ChemPartner, the service division of the Shanghai, China-based ShangPharma group, recently expanded its global footprint with the establishment of a 24,000-square-foot research facility in South San Francisco.
“In drug discovery, scientific excellence is the key to success,” said Michael Hui, ChemPartner founder and CEO. “By taking the CRO service business to the next level, this new facility will help enable our customers, partners and business collaborators to interrogate the most complex of drug discovery projects.”
ChemPartner’s new research facility will be staffed by experienced drug research scientists from biotechnology companies who will collaborate closely with ChemPartner’s scientists based in China.
“In addition to proximity to the top industry talent, the new facility brings ChemPartner services closer to the biopharmaceutical communities in the U.S., and will enable us to develop more innovative ways to bring value to our partners,” said Hui.
The company said the new facility is the first step in a planned build-out of ChemPartner’s research presence in major innovation hubs around the world.